^
Association details:
| Biomarker: | DKC1 overexpression |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | sunitinib (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma
Published date:
07/12/2023
Excerpt:
Analyses of the IMmotion 151 ccRCC cohort treated with the TKR inhibitor Sunitinib showed that female patients in the DKC1-high group was significantly associated with lower response rates (P = 0.021) accompanied by markedly shortened PFS (6.1 vs 14.2 months, P = 0.004).
DOI:
10.1186/s13293-023-00526-7